By doing early screening, it’s possible for researchers to accelerate process development and move to commercial bsAb ...

Ordspono is a CD20xCD3 bispecific monoclonal antibody that facilitates T cell engagement for the targeted killing of ...

Stay updated on promising new treatments for Diffuse Large B-cell Lymphoma and B-cell acute lymphoblastic leukemia in this ...

Medigene announces KRAS G12V as first target for TCR-guided T cell engagers: Planegg, Germany Tuesday, December 10, 2024, 17:00 Hrs [IST] Medigene AG, an oncology platform company ...

Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways.

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Financially, Immunocore has a strong cash position and stable revenue growth, but concerns remain about the pipeline's ...

Zymeworks is on track to advance five drug candidates into clinical trials in solid tumors including gynecological, thoracic, ...

Research analysts at Leerink Partnrs lifted their FY2025 earnings estimates for Zura Bio in a note issued to investors on ...

Patients with multiple myeloma are living longer, thanks to a host of new immunotherapies and targeted drugs. But there is ...

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally ...